Summary: Researchers have mapped out a newly discovered genetic disease in children tha causes epileptic seizures, loss of magnesium in the urine and reduced intelligence.
Source: Aarhus University.
Two children from Europe and a child from Canada suffer from a previously unknown disease that causes epileptic seizures, loss of magnesium in urine and reduced intelligence at the same time – though unfortunately without it being possible to treat or alleviate their symptoms.
But researchers in an international consortium have now discovered what is wrong with the children aged 4, 6 and 10. Professor Bente Vilsen and her research group at the Department of Biomedicine at Aarhus University, Denmark, are part of the consortium, which also includes researchers from universities in Germany, England, Austria, the Netherlands and Canada. The research results have been published in the American Journal of Human Genetics.
Using a genetic analysis, the researchers have discovered that the disease is caused by a newly occurring mutation in one of the sodium-potassium pump’s four forms, known as the Alpha-1 form. Even though the children have exactly the same three symptoms, they do not have the same genetic defect, as the amino acids in the pump protein which are genetically altered are different, explains Bente Vilsen.
“It turns out that the form of sodium-potassium pump which mutates is found in both the kidneys and the brain. The mutation leads to the kidneys, which normally absorb magnesium, instead secreting the substance in the urine; however, it is not the loss of magnesium which triggers the epileptic seizures. The convulsions occur because the sodium-potassium pump is also extremely important for the brain’s functions, meaning that giving extra magnesium supplements won’t help prevent the seizures,” says Bente Vilsen.
She adds that the third frightening sign of the disease, mental retardation, should probably be attributed to a lack of oxygen to the brain during the seizures.
The children share the common trait that the mutations have destroyed the pump functioning that Jens Christian Skou received the Nobel Prize in Chemistry in 1997 for discovering. This knowledge is important because understanding the role of the sodium-potassium pump is the first step towards developing effective treatment methods. The research group is now working towards this goal, even though the disease is most likely rare.
“But three cases have turned up in two different places in Europe and in Canada, and they’re not likely to be the only ones,” says Bente Vilsen. She explains that the new knowledge about the disease will probably mean that medical doctors will in future be more aware that loss of magnesium in combination with epilepsy may be caused by genetic defects in the sodium-potassium pump.
“I believe that we will in future find many more children with the disease, and that this is a good example of why international research cooperation is absolutely necessary – there are simply too few cases of the disease for a single country to carry out the research alone,” says Bente Vilsen.
She points out that in future, it will be possible to replace sick genes with healthy, and that it is therefore important to know precisely which gene is affected by a mutation. She also points out that the understanding of the disease mechanisms causing rare diseases often turns out to lead to better treatment of patients with related but far more commonly occurring diseases.
Jens Chr. Skou’s sodium-potassium pump is best known as the membrane pump that is needed for the normal functioning of nerve cells, kidney cells and most of the body’s other cells.
The pump works like a battery that separates sodium and potassium on either side of the membrane. This creates an electrical current across the cell membrane that drives many other processes such as e.g. electric conduction along the nerve cells and the absorption of magnesium and a range of nutrients from the urine into the kidney cells, so that they are not normally lost in the urine.
Jens Christian Skou, who died in early summer at the age of 99, originally had the idea that mutations in the sodium-potassium pump would be incompatible with life. But it has since been found that more serious diseases which are not necessarily fatal are due to genetic defects in the sodium-potassium pump – and this is precisely the case with the disease that the three children suffer from.
This is due to two factors. Firstly, that in the body’s different types of tissues there are several variants of the sodium-potassium pump which are able to supplement each other if one of the forms does not work. And, secondly, that we have genetic material from both our parents, so even in the kidneys, which in contrast to the brain only contain one variant of the sodium-potassium pump (Alpha-1), not all of the sodium-potassium pumps will be defective, but only those derived from one of the two parents.
Therefore, in both the brain and kidneys, there will be a reduced number of functioning sodium-potassium pumps, but not a total absence of pumps – because if this was the case, the children would have died before birth as predicted by Jens Christian Skou.
In the specific research project, the patients were discovered by medical doctors working in clinical practice. Bente Vilsen’s group have contributed with their expertise in examining sick sodium-potassium pumps by inserting the diseased gene in cultured cells that originally come from monkey kidneys, making it possible to measure their pump function in the laboratory. As it turned out, the three mutations each in their own way caused the pump to be unable to transport sodium and potassium.
There is a long way to go before the research results benefit the patients as the discovery is as such basic research. However, Bente Vilsen explains that Postdoc Rikke Holm from her research group recently discovered how it was possible to use an additional mutation – a so-called ‘rescue’ mutation – to nullify the effects of the disease mutations on the pump’s binding of sodium.
“This provides an insight into the molecular mechanism which we in the research group are working to utilise to improve the pump’s transport activities, meaning that we can possibly one day develop a drug with a similar ‘rescue-effect’. In any event, that’s our hope. The fact is that it’s basic research which generates the knowledge that forms the basis for the development of the vast majority of drugs and forms of treatment,” points out Bente Vilsen.
Funding: Independent Research Fund Denmark | Medical Sciences, Lundbeck Foundation funded the study.
Source: Bente Vilsen – Aarhus University
Publisher: Organized by NeuroscienceNews.com.
Image Source: NeuroscienceNews.com image is in the public domain.
Original Research: Abstract for “Germline De Novo Mutations in ATP1A1 Cause Renal Hypomagnesemia, Refractory Seizures, and Intellectual Disability” by Karl P. Schlingmann 16
Sascha Bandulik, Cherry Mammen, Maja Tarailo-Graovac, Rikke Holm, Matthias Baumann, Jens König, Jessica J.Y. Lee, Britt Drögemöller, Katrin Imminger, Bodo B. Beck, Janine Altmüller, Holger Thiele, Siegfried Waldegger, William van’t Hoff, Robert Kleta, Richard Warth, Clara D.M. van Karnebeek, Bente Vilsen, Detlef Bockenhauer, and Martin Konrad in American Journal of Human Genetics. Published November 1 2018.
Germline De Novo Mutations in ATP1A1 Cause Renal Hypomagnesemia, Refractory Seizures, and Intellectual Disability
Over the last decades, a growing spectrum of monogenic disorders of human magnesium homeostasis has been clinically characterized, and genetic studies in affected individuals have identified important molecular components of cellular and epithelial magnesium transport. Here, we describe three infants who are from non-consanguineous families and who presented with a disease phenotype consisting of generalized seizures in infancy, severe hypomagnesemia, and renal magnesium wasting. Seizures persisted despite magnesium supplementation and were associated with significant intellectual disability. Whole-exome sequencing and conventional Sanger sequencing identified heterozygous de novo mutations in the catalytic Na +, K +-ATPase α1 subunit ( ATP1A1). Functional characterization of mutant Na +, K +-ATPase α1 subunits in heterologous expression systems revealed not only a loss of Na +, K +-ATPase function but also abnormal cation permeabilities, which led to membrane depolarization and possibly aggravated the effect of the loss of physiological pump activity. These findings underline the indispensable role of the α1 isoform of the Na +, K +-ATPase for renal-tubular magnesium handling and cellular ion homeostasis, as well as maintenance of physiologic neuronal activity.